Kamya Moses
ID: UNCST-2020-R014203
|
Enhancing immunity to malaria in young children with effective chemoprevention
REFNo: HS1763ES
To compare the incidence of malaria from 4 weeks to 4 years of age among children born to mothers randomized to receive intermittent preventative therapy in pregnancy (IPTp) with monthly sulfadoxine pyrimethamine (SP) alone, monthly DP alone, or both monthly SP+DP.
To compare the incidence of malaria from 2-4 years of age among children randomized to receive IPT in childhood (IPTc) with monthly DP from 8 weeks to 1 year of age vs. monthly DP from 8 weeks to 2 year of age vs. no IPTc.
To compare innate and adaptive effector and regulatory responses between children randomized to different IPT arms.
|
Uganda |
2021-11-24 |
2024-11-24 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Emmanuel Viga Emmanuel
ID:
|
MORAL AND SOCIAL DIMENSIONS OF ACCOUNTABILITY IN CIVIC HUMANITARIANISM: RELATIONAL AID AMONGST SOUTH SUDANESE REFUGEES IN UGANDA
REFNo: SS832ES
This research will majorly attempt to answer the question How is accountability of relational aid in civic humanitarianism conceptualized and managed in protracted crisis. This will be achieved by answering the following sub questions:-
1. What differentiates civic humanitarianism from mainstream humanitarian actors?
2. What is relational aid within civic humanitarianism? and how is accountability understood within the concept of relational aid?
3. What are the accountability practices in civic humanitarian aid?
4- How do different accountability forms influence aid delivery?
|
Uganda |
2021-11-23 |
2024-11-23 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
DAN NYEHANGANE
ID:
|
CYCLOTIDES FROM MEDICINAL PLANTS OF UGANDA: SELECTED SOURCES, ANTIBACTERIAL ACTIVITY, AND CYTOTOXICITY
REFNo: NS258ES
Primary Objective: To identify cyclotides from selected medicinal plants in Uganda and establish their antibacterial activity and cytotoxicity, in order to provide a basis for their medical application in Uganda.
Specific Objectives
1.To determine the presence and quantities of cyclotides in different parts of selected medicinal plant species from selected families reported to express cyclotides and are used to treat bacterial infections in Uganda.
2.To characterize the activity of cyclotides from Ugandan plants in relation to sequence, size and structure
3.To determine antibacterial activities of cyclotides isolated from the different plant species stratified by the plant part extracted and season of harvesting the plant.
4.To determine the cytotoxic effect of the most active antibacterial cyclotide on mammalian cells
5.To determine the synergistic activity of the most active cyclotides against bacterial strains by using combinations of cyclotides from different plant species
6.To establish the anti-biofilm and immunomodulatory activity of the most active anti-bacterial cyclotides
|
Uganda |
2021-11-23 |
2024-11-23 |
Natural Sciences |
Non-Clinical Trial |
Degree Award |
|
Brenda McCollum
ID:
|
Muslims and Islam in Buganda, ca. 1900 - 1962
REFNo: SS950ES
I seek to examine the Muslim experience of colonialism in the Kingdom of Buganda.
|
USA |
2021-11-23 |
2024-11-23 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Rebecca Nalwanga Nalwanga
ID:
|
Exploring the Social and Institutional Dimensions of Disability in Primary Education: The Case of Inclusive Development in Uganda
REFNo: SS985ES
This research project aims to better understand the relationship between social development and disability in low-income countries. To achieve this objective, the research project will focus on how the experiences and positionality of primary school learners with a disability intersect with social development, education and democracy, and how these intersections can inform policy and practices to advance social, economic and political development in a low-income country such as Uganda.
|
Uganda |
2021-11-22 |
2024-11-22 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Faith Masette Bisikwa
ID:
|
Exploring Classroom Assessment Practices and its Impact on Preservice Teachers’ self-efficacy in a selected Primary Teachers college, Uganda
REFNo: SS993ES
I used questions instead of objectives
Main Question; How do tutors’ classroom assessment practices impact preservice teacher’s self-efficacy?
Subsidiary questions;
1.What are the common classroom assessment practices in Ugandan Primary teachers’ colleges?
2.How is classroom assessment, practiced in this PTC?
3.What is the relationship between assessment practices and preservice teacher’s self-efficacy?
4.How best can classroom assessment practices be done in PTCs to improve Preservice teachers’ self-efficacy?
|
Uganda |
2021-11-22 |
2024-11-22 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Cissy Kityo
ID: UNCST-2021-R013663
|
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19
(Adapt Out COVID)
REFNo: HS1813ES
1.1 Co-Primary Objectives
1.1.1 Phases II and III: To evaluate safety of the investigational agent.
1.1.2 Phase II: To determine efficacy of the investigational agent to reduce the duration of COVID-19 symptoms through study day 28.
1.1.3 Phase II: To determine the efficacy of the investigational agent to increase the proportion of participants with nasopharyngeal (NP) SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) at study days 3, 7, and 14.
1.1.4 Phase III: To determine if the investigational agent will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study day 28. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19 during the COVID-19 pandemic.
1.2 Secondary Objectives
1.2.1 Phases II and III: To determine whether the investigational agent reduces a COVID-19 Severity Ranking scale based on COVID-19-associated symptom burden (severity and duration), hospitalization, and death, through study day 28.
1.2.2 Phase II and III: To determine whether the investigational agent reduces the progression of COVID-19-associated symptoms.
1.2.3 Phase II and III: To determine if the investigational agent reduces levels of SARS-CoV-2 RNA in NP swabs.
1.2.4 Phase III: To determine the efficacy of the investigational agent to increase the proportion of participants with NP SARS-CoV-2 RNA below the LLoQ at study day 3.
1.2.5 Phase II: To determine the pharmacokinetics of the investigational agent.
1.2.6 Phase II: To determine efficacy of the investigational agent to obtain pulse oximetry measurement of ≥96% through day 28.
1.2.7 Phase III: To determine if the investigational agent will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study week 72.
1.2.8 Phase III: To evaluate if the investigational agent reduces the time to sustained symptom resolution through study day 28.
|
Uganda |
2021-11-22 |
2024-11-22 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Francis Ssali
ID: UNCST-2021-R012134
|
A Phase 2, Open-label, Single-arm, Multicentre Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to less than 12 years) who are Virologically Suppressed (TMC278HTX2002)
REFNo: HS1815ES
Primary Endpoints
• Area under the plasma concentration-time curve from the time of administration up to 24 hours post-dose of RPV, as derived from the intensive PK assessments.
• Incidence of grade 3/4 AEs, SAEs, HIV-related events (including acquired immune deficiency syndrome [AIDS]-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment.
Secondary Endpoint
• Incidence and severity of AEs/HIV-related events and their relatedness to RPV through 24 and 48 weeks of study treatment.
• Change from baseline Movement.
• Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.
• Treatment adherence, as assessed by the Pediatric European Network for the Treatment of AIDS (PENTA) adherence questionnaire and by study intervention accountability, through 24 and 48 weeks of study treatment.
|
Uganda |
2021-11-22 |
2024-11-22 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jerome Kabakyenga Kahuma
ID: UNCST-2021-R013729
|
The A-Lite vein locator: “a non-invasive assistive medical device designed to improve vein visibility among patients requiring intravenous therapy.â€
REFNo: HS1547ES
Main Objective
1. To assess the efficacy, safety and impact of using an assistive medical device to aid vein visibility among patients requiring intravenous therapy.
Specific Objectives
1. To assess the safety and efficacy of the A-Lite vein locator among 10 adults in Uganda.
2. To investigate non-inferiority by assessing the performance of the A-Lite vein locator with respect to the existing standard of care among 48 adolescents in Uganda.
3. To determine the effectiveness of using the A-Lite vein locator for improving vein visibility among 156 children requiring intravenous cannulation in Uganda.
|
Uganda |
2021-11-19 |
2024-11-19 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Clare Tanton Tanton
ID:
|
Taking the Good School Toolkit to scale
REFNo: SS1035ES
The aim of the project is to determine the feasibility and acceptability of using Regional Resource Persons to deliver the Good Schools Toolkit in primary and secondary schools in Uganda and to relate markers of implementation to intermediate outcomes in teachers.
The specific objectives are:
1. To determine whether implementation of the Good Schools Toolkit through Regional Resource Persons can be done with fidelity and whether it is associated with attitudes towards violence against children and markers of school operating culture among teachers.
2. To understand Teacher Protagonists’ motivations, their perceptions of their role and how these evolve during intervention implementation. To understand Teacher Protagonists’ experiences and opinions of intervention mode of delivery and the support they receive from Regional Resource Persons and school administration, and their views on the main successes and challenges of this approach.
3. To understand the experiences of Regional Resource Persons in supporting schools and at different stages of intervention implementation. To understand Regional Resource Persons’ perceptions of the main successes and challenges they face during intervention implementation and how these challenges might be overcome.
4. To explore how the attitudes and behaviours of the Regional Resource Persons evolve following Good Schools Toolkit training and during their role supporting schools, and how this correlates with their performance.
5. To understand teachers’ experiences returning to school after prolonged COVID-related closures
|
UK |
2021-11-19 |
2024-11-19 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|